What Happened?
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Therapeutics company Moderna (NASDAQ: MRNA) fell 3.3%. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Imaging, Diagnostics company Lantheus (NASDAQ: LNTH) fell 4.7%. Is now the time to buy Lantheus? Access our full analysis report here, it’s free.
- Health Insurance Providers company Centene (NYSE: CNC) fell 3.9%. Is now the time to buy Centene? Access our full analysis report here, it’s free.
- Specialized Medical & Nursing Services company AMN Healthcare Services (NYSE: AMN) fell 3.1%. Is now the time to buy AMN Healthcare Services? Access our full analysis report here, it’s free.
- Testing & Diagnostics Services company NeoGenomics (NASDAQ: NEO) fell 7%. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
Zooming In On NeoGenomics (NEO)
NeoGenomics’s shares are extremely volatile and have had 33 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 7 days ago when the stock dropped 3.5% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
NeoGenomics is down 61.8% since the beginning of the year, and at $6.30 per share, it is trading 66.1% below its 52-week high of $18.61 from January 2025. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $169.71.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
